TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ: ABPI) has entered into mutual confidentiality agreements with several pharmaceutical companies that have established respiratory care franchises. These companies have approached Accentia regarding SinuNase™, a unique formulation of low-dose intranasal amphotericin B, in development for the treatment of chronic sinusitis. Accentia believes that potential relationships with appropriate pharmaceutical partners could provide upfront and milestone payments as well as enhance the commercial opportunity for SinuNase, especially within the primary care market in the U.S. and in international markets.